Category: Previous G-BA decisions

Here are the latest G-BA decisions from the G-BA meeting held on 20 Aug 2026 on the early benefit assessments of Dawnzera, Colxi, Verzenios, Tepezza, Mounjaro, Elucirem and Tibsovo. A database of all previous G-BA resolutions is available in my store. Dawnzera (donidalorsen); Hereditary angioedema, prophylaxis, ≥ 12 years – Hint of minor additional benefit…

Here are the latest G-BA decisions from the G-BA meeting held on 6 Aug 2026 on the early benefit assessments of Recarbrio, Teizeild, Winrevair, Aspaveli, Koselugo and Ziihera. A database of all previous G-BA resolutions is available in my store. Recarbrio (imipenem/cilastatin/relebactam); new indication: bacterial infections, multiple indications, < 18 years – Reserve antibiotic, Additional…

Here are the latest G-BA decisions from the G-BA meeting held on 16 July on the early benefit assessments of Elahere and Xerava. A database of all previous G-BA resolutions is available in my store. Elahere (mirvetuximab soravtansine); ovarian, fallopian tube, or primary peritoneal carcinoma; FRα-positive; platinum-resistant; after 1 to 3 prior lines of therapy -…

Here are the latest G-BA decisions from the G-BA meeting held on 2 July on the early benefit assessments of Loqtorzi and Minjuvi. This meeting also marked the first meeting of new G-BA chair Dr Sonja Optendrenk. A database of all previous G-BA resolutions is available in my store. Loqtorzi (toripalimab): Relapsed or metastatic nasopharyngeal…

Here are the latest G-BA decisions from the G-BA meeting held on 18 June 2026 on the early benefit assessments of Retsevmo, Imaavy, Byfavo and Tremfya – all negative!. This meeting also marked the 300th and last session of G-BA chair Josef Hecken. Going forward, Dr Sonja Optendrenk will fill this role. A database of…

Here are the latest G-BA decisions from the G-BA meeting held on 4 June 2026 on the early benefit assessments of Opdivo (last one!), Libtayo, Breyanzi, Fabhalta, and Paxlovid. A database of all previous G-BA resolutions is available in my store. Opdivo (nivolumab); urothelial carcinoma, PD-L1 expression ≥ 1%, adjuvant therapy; re-assessment after expiry of…

Here are the latest G-BA decisions from the G-BA meeting held on 21 May 2026 on the early benefit assessments of Keytruda, Scemblix and Tryngolza. A database of all previous G-BA resolutions is available in my store. Tryngolza (olezarsen); Chylomicronemia syndrome – Orphan drug, Indication of minor additional benefit Scemblix (asciminib); new indication: Chronic myeloid…

Here are the latest G-BA decisions from the G-BA meeting held on 7 May 2026 on the early benefit assessments of Koselugo, Ayvaykt, Voranigo, Tezspire, and Attrogy. And we saw an unquantifiable additional benefit being assigned based on a single-arm trial!!! The G-BA accepted the benefit of Koselugo in the paediatric indication on reduction in…

Here are the latest G-BA decisions from the G-BA meeting held on 16 April 2026 on the early benefit assessments of Romvimza, Kisunla, Omjjara and Ayvakyt. A database of all previous G-BA resolutions is available in my store. Romvimza (vimseltinib); Symptomatic tenosynovial giant cell tumours – Orphan drug, Indication of considerable additional benefit Kisunla (donanemab);…

Here are the latest G-BA decisions from the G-BA meeting held on 2 April 2026 on the early benefit assessments of Ekterly, Ogsiveo, and on the RWE of Roctavian. A database of all previous G-BA resolutions is available in my store. Ekterly (sebetralstat): Hereditary angioedema, acute treatment, ≥ 12 years – Orphan drug, Hint of…